National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019

PB 114 of 2019

made under subsection 98C(1) of the

National Health Act 1953

Compilation No. 58

Compilation date: 1 August 2025

Includes amendments: F2025L00879

Prepared by the Office of Parliamentary Counsel, Canberra

About this compilation

This compilation

This is a compilation of the *National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019* that shows the text of the law as amended and in force on 1 August 2025 (the ***compilation date***).

The notes at the end of this compilation (the ***endnotes***) include information about amending laws and the amendment history of provisions of the compiled law.

Uncommenced amendments

The effect of uncommenced amendments is not shown in the text of the compiled law. The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. Any uncommenced amendments affecting the law are accessible on the Register (www.legislation.gov.au).

Application, saving and transitional provisions

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

Editorial changes

For more information about any editorial changes made in this compilation, see the endnotes.

Presentational changes

The *Legislation Act 2003* provides for First Parliamentary Counsel to make presentational changes to a compilation. Presentational changes are applied to give a more consistent look and feel to legislation published on the Register, and enable the user to more easily navigate those documents.

Modifications

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. Any modifications affecting the law are accessible on the Register.

Self-repealing provisions

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

Contents

Part 1—Preliminary

1 Name

(1) This instrument is the *National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019*.

(2) This instrument may also be cited as PB 114 of 2019.

3 Authority

This instrument is made under subsection 98C(1) of the *National Health Act 1953*.

5 Simplified outline of this instrument

The Commonwealth price for pharmaceutical benefits supplied by an approved medical practitioner is worked out in the same way as the Commonwealth price for those benefits supplied by an approved pharmacist.

The Commonwealth will pay an approved medical practitioner or an approved pharmacist for supply of a pharmaceutical benefit only if certain conditions are met. They are as follows:

(a) if a determination under subsection 85(6) of the Act specifies a brand of the benefit, payment will be made only for supply of that brand of the benefit;

(b) if the benefit is specified in Schedule 4 to this instrument, payment will be made for supply of the benefit only if it is supplied in a complete pack.

Schedules 1, 2, 3 and 5 list pharmaceutical benefits and ingredients of pharmaceutical benefits for which particular rules apply for working out the Commonwealth price (whether the benefits are supplied by an approved medical practitioner or an approved pharmacist).

Schedule 4 lists pharmaceutical benefits that must be supplied in complete packs by an approved medical practitioner or an approved pharmacist for the practitioner or pharmacist to be paid by the Commonwealth for the supply.

6 Definitions

In this instrument:

Act means the *National Health Act 1953*.

approved medical practitioner has the meaning given by subsection 84(1) of the Act.

approved pharmacist has the meaning given by subsection 84(1) of the Act.

brand has the meaning given by subsection 84(1) of the Act.

extemporaneously-prepared pharmaceutical benefit has the meaning given by subsection 6(1) of the *Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2020* (PB 66 of 2020).

listed drug has the meaning given by subsection 84(1) of the Act.

pharmaceutical benefit has the meaning given by subsection 84(1) of the Act.

pharmaceutical item has the meaning given by section 84AB of the Act.

Part 2—Commonwealth price for pharmaceutical benefits supplied by approved medical practitioners

7 Commonwealth price for pharmaceutical benefits supplied by approved medical practitioners

(1) For the purposes of paragraph 98C(1)(a) of the Act, this section provides for the manner of ascertaining the Commonwealth price for a quantity, or number of units, of a pharmaceutical benefit supplied by an approved medical practitioner, for the purposes of a payment to the practitioner in respect of the supply.

(2) The Commonwealth price is to be ascertained in the same manner as the Commonwealth price for the supply would have been worked out under the *Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2020* (PB 66 of 2020) if the supply had been made by an approved pharmacist.

(3) Schedules 1, 2, 3 and 5 identify pharmaceutical benefits and ingredients in relation to which particular rules for ascertaining the Commonwealth price apply.

Note: Those rules are in the *Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2020* (PB 66 of 2020), which is relevant because of subsection (2) of this section.

Part 3—Conditions on payments for pharmaceutical benefits supplied by approved pharmacists and approved medical practitioners

8 Scope of this Part

For the purposes of paragraph 98C(1)(b) of the Act, this Part sets out the conditions subject to which payments will be made by the Commonwealth in respect of the supply of pharmaceutical benefits by approved pharmacists and approved medical practitioners.

9 Condition on payment for supply of certain pharmaceutical items

If a determination under subsection 85(6) of the Act is in force for a brand of a pharmaceutical item consisting of a drug or medicinal preparation, payments will be made by the Commonwealth in respect of the supply of the drug or preparation only if that brand is supplied.

10 Payment for supply of certain pharmaceutical benefits in complete packs

Payments will be made by the Commonwealth in respect of the supply of a listed drug in a form described in columns 1 and 2 of an item of Schedule 4 only if the quantity supplied is the quantity contained in a unit of the size described in column 2 of the item (even if the prescription for the supply is for supply of a lesser quantity).

Schedule 1—Ready-prepared pharmaceutical benefits that are mixtures of ready-prepared ingredients

Note: See subsection 7(3).

Ready-prepared pharmaceutical benefits that are mixtures of ready-prepared ingredients	
Column 1 **Listed drug with water purified - BP**	**Column 2** **Form**
Amoxicillin	Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL
Amoxicillin	Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL
Amoxicillin	Powder for oral suspension 500 mg (as trihydrate) per 5 mL, 100 mL
Amoxicillin	Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL
Amoxicillin with clavulanic acid	Powder for oral suspension containing 125 mg amoxicillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 75 mL
Amoxicillin with clavulanic acid	Powder for oral suspension containing 400 mg amoxicillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL
Azithromycin	Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL
Cefaclor	Powder for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL
Cefaclor	Powder for oral suspension 250 mg (as monohydrate) per 5 mL, 75 mL
Cefalexin	Granules for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL
Cefalexin	Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL
Cefuroxime	Powder for oral suspension 125 mg (as axetil) per 5 mL, 70 mL (S19A)
Clarithromycin	Powder for oral liquid 250 mg per 5 mL, 50 mL
Erythromycin	Powder for oral liquid 200 mg (as ethyl succinate) per 5 mL, 100 mL
Erythromycin	Powder for oral liquid 400 mg (as ethyl succinate) per 5 mL, 100 mL
Flucloxacillin	Powder for oral liquid 125 mg (as sodium monohydrate) per 5 mL, 100 mL

Schedule 1 Ready-prepared pharmaceutical benefits that are mixtures of ready-prepared ingredients

Ready-prepared pharmaceutical benefits that are mixtures of ready-prepared ingredients	
Column 1 **Listed drug with water purified - BP**	**Column 2** **Form**
Flucloxacillin	Powder for oral liquid 250 mg (as sodium monohydrate) per 5 mL, 100 mL
Fluconazole	Powder for oral suspension 50 mg in 5 mL, 35 mL
Mycophenolic acid	Powder for oral suspension containing mycophenolate mofetil 1 g per 5 mL, 165 mL
Phenoxymethylpenicillin	Powder for oral liquid 125 mg (as potassium) per 5 mL, 100 mL
Phenoxymethylpenicillin	Powder for oral liquid 250 mg (as potassium) per 5 mL, 100 mL
Valganciclovir	Powder for oral solution 50 mg (as hydrochloride) per mL, 100 mL
Voriconazole	Powder for oral suspension 40 mg per mL, 70 mL

Schedule 2—Unstable or sterile ingredients used for extemporaneously-prepared pharmaceutical benefits

Note: See subsection 7(3).

Unstable or sterile ingredients used for extemporaneously-prepared pharmaceutical benefits
Ingredient
Water for injections—sterilised

Schedule 3—Pharmaceutical benefits for which a dangerous drug fee applies

Note: See subsection 7(3).

Pharmaceutical benefits for which a dangerous drug fee applies	
Column 1 **Listed drug**	**Column 2** **Form**
Alprazolam	Tablet 250 micrograms
Alprazolam	Tablet 500 micrograms
Alprazolam	Tablet 1 mg
Buprenorphine	Injection (modified release) 8 mg in 0.16 mL pre-filled syringe
Buprenorphine	Injection (modified release) 16 mg in 0.32 mL pre-filled syringe
Buprenorphine	Injection (modified release) 24 mg in 0.48 mL pre-filled syringe
Buprenorphine	Injection (modified release) 32 mg in 0.64 mL pre-filled syringe
Buprenorphine	Injection (modified release) 64 mg in 0.18 mL pre-filled syringe
Buprenorphine	Injection (modified release) 96 mg in 0.27 mL pre-filled syringe
Buprenorphine	Injection (modified release) 100 mg in 0.5 mL pre-filled syringe
Buprenorphine	Injection (modified release) 128 mg in 0.36 mL pre-filled syringe
Buprenorphine	Injection (modified release) 160 mg in 0.45 mL pre-filled syringe
Buprenorphine	Injection (modified release) 300 mg in 1.5 mL pre-filled syringe
Buprenorphine	Tablet (sublingual) 400 micrograms (as hydrochloride)
Buprenorphine	Tablet (sublingual) 2 mg (as hydrochloride)
Buprenorphine	Tablet (sublingual) 8 mg (as hydrochloride)
Buprenorphine	Transdermal patch 5 mg
Buprenorphine	Transdermal patch 10 mg
Buprenorphine	Transdermal patch 15 mg
Buprenorphine	Transdermal patch 20 mg
Buprenorphine	Transdermal patch 25 mg
Buprenorphine	Transdermal patch 30 mg
Buprenorphine	Transdermal patch 40 mg
Buprenorphine with naloxone	Film (soluble) 2 mg (as hydrochloride)-0.5 mg (as hydrochloride)
Buprenorphine with naloxone	Film (soluble) 8 mg (as hydrochloride)-2 mg (as hydrochloride)
Codeine	Tablet containing codeine phosphate hemihydrate 30 mg
Dexamfetamine	Tablet containing dexamfetamine sulfate 5 mg
Esketamine	Nasal spray device 28 mg in 2 actuations
Fentanyl	Lozenge 200 micrograms (as citrate)

Pharmaceutical benefits for which a dangerous drug fee applies	
Column 1 **Listed drug**	**Column 2** **Form**
Fentanyl	Lozenge 400 micrograms (as citrate)
Fentanyl	Lozenge 600 micrograms (as citrate)
Fentanyl	Lozenge 800 micrograms (as citrate)
Fentanyl	Tablet (orally disintegrating) 100 micrograms (as citrate)
Fentanyl	Tablet (orally disintegrating) 200 micrograms (as citrate)
Fentanyl	Tablet (orally disintegrating) 400 micrograms (as citrate)
Fentanyl	Tablet (orally disintegrating) 600 micrograms (as citrate)
Fentanyl	Tablet (orally disintegrating) 800 micrograms (as citrate)
Fentanyl	Tablet (sublingual) 100 micrograms (as citrate)
Fentanyl	Tablet (sublingual) 200 micrograms (as citrate)
Fentanyl	Tablet (sublingual) 300 micrograms (as citrate)
Fentanyl	Tablet (sublingual) 400 micrograms (as citrate)
Fentanyl	Tablet (sublingual) 600 micrograms (as citrate)
Fentanyl	Tablet (sublingual) 800 micrograms (as citrate)
Fentanyl	Transdermal patch 1.28 mg
Fentanyl	Transdermal patch 2.063 mg
Fentanyl	Transdermal patch 2.1 mg
Fentanyl	Transdermal patch 2.55 mg
Fentanyl	Transdermal patch 4.125 mg
Fentanyl	Transdermal patch 4.2 mg
Fentanyl	Transdermal patch 5.10 mg
Fentanyl	Transdermal patch 7.65 mg
Fentanyl	Transdermal patch 8.25 mg
Fentanyl	Transdermal patch 8.4 mg
Fentanyl	Transdermal patch 10.20 mg
Fentanyl	Transdermal patch 12.375 mg
Fentanyl	Transdermal patch 12.6 mg
Fentanyl	Transdermal patch 16.5 mg
Fentanyl	Transdermal patch 16.8 mg
Hydromorphone	Injection containing hydromorphone hydrochloride 2 mg in 1 mL
Hydromorphone	Injection containing hydromorphone hydrochloride 10 mg in 1 mL
Hydromorphone	Oral solution containing hydromorphone hydrochloride 1 mg per mL, 1 mL
Hydromorphone	Oral solution containing hydromorphone hydrochloride 1 mg per mL, 1 mL (S19A)
Hydromorphone	Tablet containing hydromorphone hydrochloride 2 mg
Hydromorphone	Tablet containing hydromorphone hydrochloride 4 mg
Hydromorphone	Tablet containing hydromorphone hydrochloride 8 mg

Pharmaceutical benefits for which a dangerous drug fee applies	
Column 1 **Listed drug**	**Column 2** **Form**
Lisdexamfetamine	Capsule containing lisdexamfetamine dimesilate 20 mg
Lisdexamfetamine	Capsule containing lisdexamfetamine dimesilate 30 mg
Lisdexamfetamine	Capsule containing lisdexamfetamine dimesilate 40 mg
Lisdexamfetamine	Capsule containing lisdexamfetamine dimesilate 50 mg
Lisdexamfetamine	Capsule containing lisdexamfetamine dimesilate 60 mg
Lisdexamfetamine	Capsule containing lisdexamfetamine dimesilate 70 mg
Methadone	Injection containing methadone hydrochloride 10 mg in 1 mL
Methadone	Oral liquid containing methadone hydrochloride 25 mg per 5 mL in 1 L bottle, 1 mL
Methadone	Oral liquid containing methadone hydrochloride 25 mg per 5 mL in 200 mL bottle, 1 mL
Methadone	Tablet containing methadone hydrochloride 10 mg
Methylphenidate	Capsule containing methylphenidate hydrochloride 10 mg (modified release)
Methylphenidate	Capsule containing methylphenidate hydrochloride 20 mg (modified release)
Methylphenidate	Capsule containing methylphenidate hydrochloride 30 mg (modified release)
Methylphenidate	Capsule containing methylphenidate hydrochloride 40 mg (modified release)
Methylphenidate	Capsule containing methylphenidate hydrochloride 60 mg (modified release)
Methylphenidate	Tablet containing methylphenidate hydrochloride 10 mg
Methylphenidate	Tablet containing methylphenidate hydrochloride 18 mg (extended release)
Methylphenidate	Tablet containing methylphenidate hydrochloride 18 mg (extended release) Concerta (Switzerland) (S19A)
Methylphenidate	Tablet containing methylphenidate hydrochloride 18 mg (extended release) (S19A)
Methylphenidate	Tablet containing methylphenidate hydrochloride 27 mg (extended release)
Methylphenidate	Tablet containing methylphenidate hydrochloride 27 mg (extended release) (S19A)
Methylphenidate	Tablet containing methylphenidate hydrochloride 36 mg (extended release)
Methylphenidate	Tablet containing methylphenidate hydrochloride 36 mg (extended release) Concerta (Switzerland) (S19A)
Methylphenidate	Tablet containing methylphenidate hydrochloride 36 mg (extended release) (S19A)
Methylphenidate	Tablet containing methylphenidate hydrochloride 54 mg (extended release)
Methylphenidate	Tablet containing methylphenidate hydrochloride 54 mg (extended release) Concerta (Switzerland) (S19A)
Methylphenidate	Tablet containing methylphenidate hydrochloride 54 mg (extended release) (S19A)
Morphine	Capsule containing morphine sulfate pentahydrate 10 mg (containing sustained release pellets)
Morphine	Capsule containing morphine sulfate pentahydrate 20 mg (containing sustained

Pharmaceutical benefits for which a dangerous drug fee applies	
Column 1 **Listed drug**	**Column 2** **Form**
	release pellets)
Morphine	Capsule containing morphine sulfate pentahydrate 50 mg (containing sustained release pellets)
Morphine	Capsule containing morphine sulfate pentahydrate 100 mg (containing sustained release pellets)
Morphine	Capsule containing morphine sulfate pentahydrate 30 mg (controlled release)
Morphine	Capsule containing morphine sulfate pentahydrate 60 mg (controlled release)
Morphine	Capsule containing morphine sulfate pentahydrate 90 mg (controlled release)
Morphine	Capsule containing morphine sulfate pentahydrate 120 mg (controlled release)
Morphine	Injection containing morphine hydrochloride trihydrate 10 mg in 1 mL
Morphine	Injection containing morphine hydrochloride trihydrate 20 mg in 1 mL
Morphine	Injection containing morphine hydrochloride trihydrate 50 mg in 5 mL
Morphine	Injection containing morphine hydrochloride trihydrate 100 mg in 5 mL
Morphine	Injection containing morphine sulfate pentahydrate 10 mg in 1 mL
Morphine	Injection containing morphine sulfate pentahydrate 15 mg in 1 mL
Morphine	Injection containing morphine sulfate pentahydrate 30 mg in 1 mL
Morphine	Oral solution containing morphine hydrochloride trihydrate 2 mg per mL, 1 mL
Morphine	Oral solution containing morphine hydrochloride trihydrate 5 mg per mL, 1 mL
Morphine	Oral solution containing morphine hydrochloride trihydrate 10 mg per mL, 1 mL
Morphine	Oral solution containing morphine hydrochloride trihydrate 10 mg per mL, 1 mL (S19A)
Morphine	Oral solution containing morphine sulfate 2 mg per mL in 100 mL bottle, 1 mL (S19A)
Morphine	Oral solution containing morphine sulfate 2 mg per mL in 500 mL bottle, 1 mL (S19A)
Morphine	Oral solution containing morphine sulfate 10 mg per 5 mL in 100 mL bottle, 1 mL (S19A)
Morphine	Oral solution containing morphine sulfate 10 mg per 5 mL in 300 mL bottle, 1 mL (S19A)
Morphine	Tablet containing morphine sulfate pentahydrate 10 mg
Morphine	Tablet containing morphine sulfate pentahydrate 20 mg
Morphine	Tablet containing morphine sulfate pentahydrate 30 mg
Morphine	Tablet containing morphine sulfate pentahydrate 5 mg (controlled release)
Morphine	Tablet containing morphine sulfate pentahydrate 10 mg (controlled release)
Morphine	Tablet containing morphine sulfate pentahydrate 15 mg (controlled release)
Morphine	Tablet containing morphine sulfate pentahydrate 30 mg (controlled release)
Morphine	Tablet containing morphine sulfate pentahydrate 60 mg (controlled release)
Morphine	Tablet containing morphine sulfate pentahydrate 100 mg (controlled release)

Pharmaceutical benefits for which a dangerous drug fee applies	
Column 1 **Listed drug**	**Column 2** **Form**
Morphine	Tablet containing morphine sulfate pentahydrate 200 mg (controlled release)
Oxycodone	Capsule containing oxycodone hydrochloride 5 mg
Oxycodone	Capsule containing oxycodone hydrochloride 10 mg
Oxycodone	Capsule containing oxycodone hydrochloride 20 mg
Oxycodone	Oral solution containing oxycodone hydrochloride 1 mg per mL, 1 mL
Oxycodone	Suppository 30 mg (as pectinate)
Oxycodone	Tablet containing oxycodone hydrochloride 5 mg
Oxycodone	Tablet containing oxycodone hydrochloride 10 mg (controlled release)
Oxycodone	Tablet containing oxycodone hydrochloride 15 mg (controlled release)
Oxycodone	Tablet containing oxycodone hydrochloride 20 mg (controlled release)
Oxycodone	Tablet containing oxycodone hydrochloride 30 mg (controlled release)
Oxycodone	Tablet containing oxycodone hydrochloride 40 mg (controlled release)
Oxycodone	Tablet containing oxycodone hydrochloride 80 mg (controlled release)
Oxycodone with naloxone	Tablet (controlled release) containing oxycodone hydrochloride 2.5 mg with naloxone hydrochloride 1.25 mg
Oxycodone with naloxone	Tablet (controlled release) containing oxycodone hydrochloride 5 mg with naloxone hydrochloride 2.5 mg
Oxycodone with naloxone	Tablet (controlled release) containing oxycodone hydrochloride 10 mg with naloxone hydrochloride 5 mg
Oxycodone with naloxone	Tablet (controlled release) containing oxycodone hydrochloride 15 mg with naloxone hydrochloride 7.5 mg
Oxycodone with naloxone	Tablet (controlled release) containing oxycodone hydrochloride 20 mg with naloxone hydrochloride 10 mg
Oxycodone with naloxone	Tablet (controlled release) containing oxycodone hydrochloride 30 mg with naloxone hydrochloride 15 mg
Oxycodone with naloxone	Tablet (controlled release) containing oxycodone hydrochloride 40 mg with naloxone hydrochloride 20 mg
Oxycodone with naloxone	Tablet (controlled release) containing oxycodone hydrochloride 60 mg with naloxone hydrochloride 30 mg
Oxycodone with naloxone	Tablet (controlled release) containing oxycodone hydrochloride 80 mg with naloxone hydrochloride 40 mg
Tapentadol	Tablet (modified release) 50 mg (as hydrochloride)
Tapentadol	Tablet (modified release) 100 mg (as hydrochloride)
Tapentadol	Tablet (modified release) 150 mg (as hydrochloride)
Tapentadol	Tablet (modified release) 200 mg (as hydrochloride)
Tapentadol	Tablet (modified release) 250 mg (as hydrochloride)

Schedule 4—Pharmaceutical benefits to be supplied as complete packs only

Note: See section 10.

Pharmaceutical benefits to be supplied as complete packs only	
Column 1 **Listed drug**	**Column 2** **Form**
Abiraterone and methylprednisolone	Pack containing 120 tablets abiraterone acetate 125 mg and 30 tablets methylprednisolone 4 mg
Abiraterone and methylprednisolone	Pack containing 120 tablets abiraterone acetate 125 mg and 60 tablets methylprednisolone 4 mg
Aciclovir	Eye ointment 30 mg per g, 4.5 g
Aclidinium	Powder for oral inhalation in breath actuated device 322 micrograms (as bromide) per dose, 60 doses
Aclidinium with formoterol	Powder for oral inhalation in breath actuated device containing aclidinium 340 micrograms (as bromide) with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses
Adapalene with benzoyl peroxide	Gel 1 mg-25 mg per g, 30 g
Amoxicillin	Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL
Amoxicillin	Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL
Amoxicillin	Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL
Amoxicillin	Powder for oral suspension 500 mg (as trihydrate) per 5 mL, 100 mL
Amoxicillin with clavulanic acid	Powder for oral suspension containing 125 mg amoxicillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 75 mL
Amoxicillin with clavulanic acid	Powder for oral suspension containing 400 mg amoxicillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL
Apremilast	Pack containing 4 tablets 10 mg, 4 tablets 20 mg and 19 tablets 30 mg
Atenolol	Oral solution 50 mg in 10 mL, 300 mL
Atovaquone	Oral suspension 750 mg per 5 mL, 210 mL
Atropine	Eye drops containing atropine sulfate monohydrate 10 mg per mL, 15 mL

Pharmaceutical benefits to be supplied as complete packs only	
Column 1 **Listed drug**	**Column 2** **Form**
Azithromycin	Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL
Beclometasone	Pressurised inhalation containing beclometasone dipropionate 50 micrograms per dose, 200 doses (CFC-free formulation)
Beclometasone	Pressurised inhalation containing beclometasone dipropionate 100 micrograms per dose, 200 doses (CFC-free formulation)
Beclometasone	Pressurised inhalation in breath actuated device containing beclometasone dipropionate 50 micrograms per dose, 200 doses (CFC-free formulation)
Beclometasone	Pressurised inhalation in breath actuated device containing beclometasone dipropionate 100 micrograms per dose, 200 doses (CFC-free formulation)
Beclometasone with formoterol	Pressurised inhalation containing beclometasone dipropionate 100 micrograms and formoterol fumarate dihydrate 6 micrograms per dose,120 dose
Beclometasone with formoterol	Pressurised inhalation containing beclometasone dipropionate 200 micrograms and formoterol fumarate dihydrate 6 micrograms per dose, 120 doses
Beclometasone with formoterol and glycopyrronium	Pressurised inhalation containing beclometasone dipropionate 100 micrograms with formoterol fumarate dihydrate 6 micrograms and glycopyrronium 10 micrograms (as bromide) per dose, 120 doses
Beclometasone with formoterol and glycopyrronium	Pressurised inhalation containing beclometasone dipropionate 200 micrograms with formoterol fumarate dihydrate 6 micrograms and glycopyrronium 10 micrograms (as bromide) per dose, 120 doses
Benzydamine	Mouth and throat rinse containing benzydamine hydrochloride 22.5 mg per 15 mL, 500 mL
Betaine	Oral powder 180 g
Betaxolol	Eye drops, solution, 5 mg (as hydrochloride) per mL, 5 mL
Bimatoprost	Eye drops 300 micrograms per mL, 3 mL
Bimatoprost	Eye drops 300 micrograms per mL, single dose units 0.4 mL, 30

Pharmaceutical benefits to be supplied as complete packs only	
Column 1 **Listed drug**	**Column 2** **Form**
Bimatoprost with timolol	Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, 3 mL
Bimatoprost with timolol	Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, single dose units 0.4 mL, 30
Brigatinib	Pack containing 7 tablets 90 mg and 21 tablets 180 mg
Brimonidine	Eye drops containing brimonidine tartrate 1.5 mg per mL, 5 mL
Brimonidine	Eye drops containing brimonidine tartrate 2 mg per mL, 5 mL
Brimonidine with timolol	Eye drops containing brimonidine tartrate 2 mg with timolol 5 mg (as maleate) per mL, 5 mL
Brinzolamide	Eye drops 10 mg per mL, 5 mL
Brinzolamide with brimonidine	Eye drops 10 mg brinzolamide with 2 mg brimonidine tartrate per mL, 5 mL
Brinzolamide with timolol	Eye drops 10 mg brinzolamide with timolol 5 mg (as maleate) per mL, 5 mL
Budesonide	Nebuliser suspension 500 micrograms in 2 mL single dose units, 30
Budesonide	Nebuliser suspension 1 mg in 2 mL single dose units, 30
Budesonide	Powder for oral inhalation in breath actuated device 100 micrograms per dose, 200 doses
Budesonide	Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses
Budesonide	Powder for oral inhalation in breath actuated device 400 micrograms per dose, 200 doses
Budesonide with formoterol	Powder for oral inhalation in breath actuated device containing budesonide 100 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses
Budesonide with formoterol	Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 60 doses
Budesonide with formoterol	Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses

Pharmaceutical benefits to be supplied as complete packs only	
Column 1 **Listed drug**	**Column 2** **Form**
Budesonide with formoterol	Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses
Budesonide with formoterol	Pressurised inhalation containing budesonide 100 micrograms with formoterol fumarate dihydrate 3 micrograms per dose, 120 doses
Budesonide with formoterol	Pressurised inhalation containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses
Budesonide with glycopyrronium and formoterol	Pressurised inhalation containing budesonide 160 micrograms with glycopyrronium 7.2 micrograms and formoterol fumarate dihydrate 5 micrograms per dose, 120 doses
Buprenorphine	Injection (modified release) 100 mg in 0.5 mL pre-filled syringe
Buprenorphine	Injection (modified release) 300 mg in 1.5 mL pre-filled syringe
Calcipotriol with betamethasone	Foam containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g
Calcipotriol with betamethasone	Ointment containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g
Captopril	Oral solution 5 mg per mL, 95 mL
Carbamazepine	Oral suspension 100 mg per 5 mL, 300 mL
Carbomer	Eye gel 2 mg per g, 10 g
Carmellose	Eye drops containing carmellose sodium 5 mg per mL, 10 mL
Carmustine	Implants 7.7 mg, 8
Cefaclor	Powder for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL
Cefaclor	Powder for oral suspension 250 mg (as monohydrate) per 5 mL, 75 mL
Cefalexin	Granules for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL
Cefalexin	Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL
Cefuroxime	Powder for oral suspension 125 mg (as axetil) per 5 mL, 70 mL (S19A)
Chloramphenicol	Eye drops 5 mg per mL, 10 mL

Pharmaceutical benefits to be supplied as complete packs only	
Column 1 **Listed drug**	**Column 2** **Form**
Chlorpromazine	Oral solution containing chlorpromazine hydrochloride 25 mg per 5 mL, 100 mL
Ciclesonide	Pressurised inhalation 80 micrograms per dose, 120 doses (CFC-free formulation)
Ciclesonide	Pressurised inhalation 160 micrograms per dose, 120 doses (CFC-free formulation)
Ciclosporin	Eye drops 1 mg per mL, single dose units 0.3 mL, 30
Ciprofloxacin	Ear drops 3 mg (as hydrochloride) per mL, 5 mL
Citrulline	Tablet 1 g, 300 (Citrulline Easy)
Clarithromycin	Powder for oral liquid 250 mg per 5 mL, 50 mL
Clobetasol	Cream containing clobetasol propionate 500 micrograms per g, 30 g
Clobetasol	Ointment containing clobetasol propionate 500 micrograms per g, 30 g
Clobetasol	Shampoo containing clobetasol propionate 500 micrograms per mL, 125 mL
Clonazepam	Oral liquid 2.5 mg per mL, 10 mL
Clozapine	Oral liquid 50 mg per mL, 100 mL
Degarelix	Powder for injection 120 mg (as acetate), 2, injection set
Desmopressin	Nasal spray (pump pack) containing desmopressin acetate 10 micrograms per actuation, 50 actuations, 5 mL, USP (Apotex)
Desmopressin	Nasal spray (pump pack) containing desmopressin acetate 10 micrograms per actuation, 60 actuations, 6 mL
Dexamethasone with framycetin and gramicidin	Ear drops containing dexamethasone 500 micrograms (as sodium metasulfobenzoate), framycetin sulfate 5 mg and gramicidin 50 micrograms per mL, 8 mL
Diazepam	Oral liquid 10 mg per 10 mL, 100 mL
Dorzolamide	Eye drops 20 mg (as hydrochloride) per mL, 5 mL
Dorzolamide with timolol	Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL
Drospirenone	Pack containing 24 tablets 4 mg and 4 inert tablets
Drospirenone	Pack containing 24 tablets 4 mg and 4 inert tablets, 3

Pharmaceutical benefits to be supplied as complete packs only	
Column 1 **Listed drug**	**Column 2** **Form**
Electrolyte replacement, oral	Oral rehydration salts containing glucose monohydrate 3.56 g, sodium chloride 470 mg, potassium chloride 300 mg and sodium acid citrate 530 mg per sachet, 10
Erythromycin	Powder for oral liquid 200 mg (as ethyl succinate) per 5 mL, 100 mL
Erythromycin	Powder for oral liquid 400 mg (as ethyl succinate) per 5 mL, 100 mL
Escitalopram	Oral solution 20 mg (as oxalate) per mL, 15 mL
Esomeprazole and clarithromycin and amoxicillin	Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium), 14 tablets clarithromycin 500 mg and 28 capsules amoxicillin 500 mg (as trihydrate)
Esomeprazole and clarithromycin and amoxicillin	Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium trihydrate), 14 tablets clarithromycin 500 mg and 28 capsules amoxicillin 500 mg (as trihydrate)
Estradiol	Transdermal gel (pump pack) 750 micrograms (as hemihydrate) per 1.25 g dose, 64 doses
Estradiol	Transdermal gel 1 mg (as hemihydrate) in 1 g sachet, 28
Estradiol	Transdermal patches 390 micrograms, 8
Estradiol	Transdermal patches 390 micrograms, 24 (S19A)
Estradiol	Transdermal patches 585 micrograms, 8
Estradiol	Transdermal patches 780 micrograms, 8
Estradiol	Transdermal patches 780 micrograms, 24 (S19A)
Estradiol	Transdermal patches 1.17 mg, 8
Estradiol	Transdermal patches 1.17 mg, 24 (S19A)
Estradiol	Transdermal patches 1.56 mg, 8
Estradiol	Transdermal patches 1.56 mg, 24 (Sandoz) (S19A)
Estradiol	Transdermal patches 750 micrograms (as hemihydrate), 8
Estradiol	Transdermal patches 1.5 mg (as hemihydrate), 8
Estradiol	Transdermal patches 3 mg (as hemihydrate), 8
Estradiol and estradiol with dydrogesterone	Pack containing 14 tablets estradiol 1 mg and 14 tablets estradiol 1 mg with dydrogesterone 10 mg
Estradiol and estradiol with dydrogesterone	Pack containing 14 tablets estradiol 2 mg and 14 tablets estradiol 2 mg with dydrogesterone 10 mg

Pharmaceutical benefits to be supplied as complete packs only	
Column 1 **Listed drug**	**Column 2** **Form**
Estradiol and estradiol with norethisterone	Pack containing 4 transdermal patches 780 micrograms estradiol (as hemihydrate) and 4 transdermal patches 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate
Estradiol and estradiol with norethisterone	Pack containing 4 transdermal patches 780 micrograms estradiol (as hemihydrate) and 4 transdermal patches 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate
Estradiol with norethisterone	Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8
Estradiol with norethisterone	Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8 (S19A)
Estradiol with norethisterone	Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8
Estradiol with norethisterone	Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8 (S19A)
Estriol	Pessaries 500 micrograms, 15
Estriol	Vaginal cream 1 mg per g, 15 g
Ethosuximide	Oral solution 250 mg per 5 mL, 200 mL
Ezetimibe and rosuvastatin	Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium)
Ezetimibe and rosuvastatin	Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium)
Ezetimibe and rosuvastatin	Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium)
Ezetimibe and rosuvastatin	Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium)
Fenfluramine	Oral solution 2.2 mg (as hydrochloride) per mL, 360 mL
Ferrous sulfate	Oral liquid containing 30 mg ferrous sulfate heptahydrate per mL, 250 mL
Flucloxacillin	Powder for oral liquid 125 mg (as sodium monohydrate) per 5 mL, 100 mL
Flucloxacillin	Powder for oral liquid 250 mg (as sodium monohydrate) per 5 mL, 100 mL
Fluticasone furoate	Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms per dose, 30 doses

Pharmaceutical benefits to be supplied as complete packs only	
Column 1 **Listed drug**	**Column 2** **Form**
Fluticasone furoate	Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms per dose, 30 doses
Fluticasone furoate with umeclidinium and vilanterol	Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenatate) per dose, 30 doses
Fluticasone furoate with umeclidinium and vilanterol	Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenatate) per dose, 30 doses
Fluticasone furoate with vilanterol	Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses
Fluticasone furoate with vilanterol	Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses
Fluticasone propionate	Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms per dose, 60 doses
Fluticasone propionate	Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms per dose, 60 doses
Fluticasone propionate	Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms per dose, 60 doses
Fluticasone propionate	Pressurised inhalation containing fluticasone propionate 50 micrograms per dose, 120 doses (CFC-free formulation)
Fluticasone propionate	Pressurised inhalation containing fluticasone propionate 125 micrograms per dose, 120 doses (CFC-free formulation)
Fluticasone propionate	Pressurised inhalation containing fluticasone propionate 250 micrograms per dose, 120 doses (CFC-free formulation)
Fluticasone propionate with formoterol	Pressurised inhalation containing fluticasone propionate 50 micrograms with formoterol fumarate dihydrate 5 micrograms per dose, 120 doses

Pharmaceutical benefits to be supplied as complete packs only	
Column 1 **Listed drug**	**Column 2** **Form**
Fluticasone propionate with formoterol	Pressurised inhalation containing fluticasone propionate 125 micrograms with formoterol fumarate dihydrate 5 micrograms per dose, 120 doses
Fluticasone propionate with formoterol	Pressurised inhalation containing fluticasone propionate 250 micrograms with formoterol fumarate dihydrate 10 micrograms per dose, 120 doses
Fluticasone propionate with salmeterol	Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses
Fluticasone propionate with salmeterol	Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses
Fluticasone propionate with salmeterol	Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses
Fluticasone propionate with salmeterol	Pressurised inhalation containing fluticasone propionate 50 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation)
Fluticasone propionate with salmeterol	Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation)
Fluticasone propionate with salmeterol	Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation)
Formoterol	Powder for oral inhalation in breath actuated device containing formoterol fumarate dihydrate 6 micrograms per dose, 60 doses
Formoterol	Powder for oral inhalation in breath actuated device containing formoterol fumarate dihydrate 12 micrograms per dose, 60 doses
Framycetin	Eye or ear drops containing framycetin sulfate 5 mg per mL, 8 mL
Furosemide	Oral solution 10 mg per mL, 30 mL
Glyceryl trinitrate	Sublingual spray (pump pack) 400 micrograms per dose, 200 doses

Pharmaceutical benefits to be supplied as complete packs only	
Column 1 **Listed drug**	**Column 2** **Form**
Goserelin and bicalutamide	Pack containing 1 subcutaneous implant containing goserelin 3.6 mg (as acetate) in pre-filled injection syringe and 28 tablets bicalutamide 50 mg
Goserelin and bicalutamide	Pack containing 1 subcutaneous implant containing goserelin 10.8 mg (as acetate) in pre-filled injection syringe and 28 tablets bicalutamide 50 mg
Goserelin and bicalutamide	Pack containing 1 subcutaneous implant containing goserelin 10.8 mg (as acetate) in pre-filled injection syringe and 84 tablets bicalutamide 50 mg
Haloperidol	Oral solution 2 mg per mL, 100 mL
Hyaluronic acid	Eye drops containing sodium hyaluronate 1 mg per mL, 10 mL
Hyaluronic acid	Eye drops containing sodium hyaluronate 2 mg per mL, 10 mL
Hydrocortisone	Cream containing hydrocortisone acetate 10 mg per g, 50 g
Hydrocortisone	Eye ointment containing hydrocortisone acetate 10 mg per g, 5 g
Hydrocortisone	Ointment containing hydrocortisone acetate 10 mg per g, 50 g
Hypromellose	0.3% w/v eye drops, 10 mL (preservative free)
Hypromellose	Eye drops 3 mg per mL, 10 mL
Hypromellose	Eye drops 5 mg per mL, 15 mL
Hypromellose with dextran	Eye drops containing 3 mg hypromellose 4500 with 1 mg dextran 70 per mL, 15 mL
Lacosamide	Oral solution 10 mg per mL, 200 mL
Latanoprost	Eye drops 50 micrograms per mL, 2.5 mL
Latanoprost with timolol	Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL
Leuprorelin and bicalutamide	Pack containing 1 syringe containing leuprorelin 7.5 mg (as acetate) and 28 tablets bicalutamide 50 mg
Leuprorelin and bicalutamide	Pack containing 1 syringe containing leuprorelin 22.5 mg (as acetate) and 28 tablets bicalutamide 50 mg
Leuprorelin and bicalutamide	Pack containing 1 syringe containing leuprorelin 22.5 mg (as acetate) and 84 tablets bicalutamide 50 mg

Pharmaceutical benefits to be supplied as complete packs only	
Column 1 **Listed drug**	**Column 2** **Form**
Levetiracetam	Oral solution 100 mg per mL, 300 mL
Lumacaftor with ivacaftor	Sachet containing granules, lumacaftor 75 mg and ivacaftor 94 mg
Lumacaftor with ivacaftor	Sachet containing granules, lumacaftor 100 mg and ivacaftor 125 mg
Lumacaftor with ivacaftor	Sachet containing granules, lumacaftor 150 mg and ivacaftor 188 mg
Macrogol 3350	Powder for oral solution 510 g
Macrogol 3350	Sachets containing powder for oral solution 13.125 g with electrolytes, 30
Mercaptopurine	Oral suspension containing mercaptopurine monohydrate 20 mg per mL, 100 mL
Metronidazole	Oral suspension containing metronidazole benzoate 320 mg per 5 mL, 100 mL
Metronidazole	Suppositories 500 mg, 10
Miconazole	Cream containing miconazole nitrate 20 mg per g, 30 g
Miconazole	Cream containing miconazole nitrate 20 mg per g, 70 g
Miconazole	Powder containing miconazole nitrate 20 mg per g, 30 g
Miconazole	Tincture 20 mg per mL, 30 mL
Mifepristone and misoprostol	Pack containing 1 tablet mifepristone 200 mg and 4 tablets misoprostol 200 micrograms
Mupirocin	Nasal ointment 20 mg (as calcium) per g, 3 g
Mupirocin	Nasal ointment 20 mg (as calcium) per g, 5 g
Mycobacterium bovis (Bacillus Calmette and Guerin (BCG)) Danish 1331 strain	Single dose pack containing powder for irrigation 30 mg, 4 vials
Mycophenolic acid	Powder for oral suspension containing mycophenolate mofetil 1 g per 5 mL, 165 mL
Nafarelin	Nasal spray (pump pack) 200 micrograms (as acetate) per dose, 60 doses
Naloxone	Nasal spray 1.8 mg (as hydrochloride dihydrate) in 0.1 mL single dose unit, 2
Naproxen	Oral suspension 125 mg per 5 mL, 474 mL
Naproxen	Oral suspension 125 mg per 5 mL, 474 mL (S19A)
Netupitant with palonosetron	Capsule containing netupitant 300 mg with palonosetron 500 microgram (as hydrochloride)
Nicorandil	Tablets 10 mg, 60

Pharmaceutical benefits to be supplied as complete packs only	
Column 1 **Listed drug**	**Column 2** **Form**
Nicorandil	Tablets 20 mg, 60
Nirmatrelvir and ritonavir	Pack containing 4 tablets nirmatrelvir 150 mg and 2 tablets ritonavir 100 mg, 5
Onasemnogene abeparvovec	Pack containing 1 vial solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL
Onasemnogene abeparvovec	Pack containing 1 vial solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 3 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL
Onasemnogene abeparvovec	Pack containing 1 vial solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 4 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL
Onasemnogene abeparvovec	Pack containing 1 vial solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 5 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL
Onasemnogene abeparvovec	Pack containing 1 vial solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 6 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL
Onasemnogene abeparvovec	Pack containing 1 vial solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 7 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL
Onasemnogene abeparvovec	Pack containing 1 vial solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 8 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL
Onasemnogene abeparvovec	Pack containing 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 1 vial solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL
Onasemnogene abeparvovec	Pack containing 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL
Onasemnogene abeparvovec	Pack containing 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 3 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL

Pharmaceutical benefits to be supplied as complete packs only	
Column 1 **Listed drug**	**Column 2** **Form**
Onasemnogene abeparvovec	Pack containing 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 4 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL
Onasemnogene abeparvovec	Pack containing 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 5 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL
Onasemnogene abeparvovec	Pack containing 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 6 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL
Onasemnogene abeparvovec	Pack containing 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 7 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL
Onasemnogene abeparvovec	Pack containing 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL
Onasemnogene abeparvovec	Pack containing 3 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL
Onasemnogene abeparvovec	Pack containing 4 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL
Onasemnogene abeparvovec	Pack containing 5 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL
Onasemnogene abeparvovec	Pack containing 6 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL
Onasemnogene abeparvovec	Pack containing 7 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL
Onasemnogene abeparvovec	Pack containing 8 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL
Onasemnogene abeparvovec	Pack containing 9 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL
Ondansetron	Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL
Oxybutynin	Transdermal patches 36 mg, 8
Ozanimod	Pack containing 4 capsules 230 micrograms and 3 capsules 460 micrograms
Paracetamol	Oral liquid 120 mg per 5 mL, 100 mL
Paracetamol	Oral liquid 240 mg per 5 mL, 200 mL

Pharmaceutical benefits to be supplied as complete packs only	
Column 1 **Listed drug**	**Column 2** **Form**
Paraffin	Eye drops containing liquid paraffin, glycerol, tyloxapol, poloxamer-188, trometamol hydrochloride, trometamol, cetalkonium chloride, 10 mL (preservative free)
Paraffin	Pack containing 2 tubes eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g
Peginterferon beta-1a	Pack containing single use injection pens containing 63 micrograms in 0.5 mL and 94 micrograms in 0.5 mL
Permethrin	Cream 50 mg per g, 30 g
Permethrin	Cream 50 mg per g, 60 g (S19A)
Phenytoin	Oral suspension 30 mg per 5 mL, 500 mL
Pilocarpine	Eye drops containing pilocarpine hydrochloride 10 mg per mL, 15 mL
Pilocarpine	Eye drops containing pilocarpine hydrochloride 20 mg per mL, 15 mL
Pilocarpine	Eye drops containing pilocarpine hydrochloride 40 mg per mL, 15 mL
Pimecrolimus	Cream 10 mg per g, 15 g
Polyethylene glycol 400 with propylene glycol	Eye drops 4 mg-3 mg per mL, 15 mL
Prednisolone	Oral solution 5 mg (as sodium phosphate) per mL, 30 mL
Prednisolone with phenylephrine	Eye drops containing prednisolone acetate 10 mg with phenylephrine hydrochloride 1.2 mg per mL, 10 mL
Progesterone and estradiol	Pack containing 30 capsules progesterone 100 mg (micronised) and transdermal gel (pump pack) estradiol 750 micrograms (as hemihydrate) per 1.25 g dose, 64 doses
Propylene glycol	Eye drops 60 micrograms per mL, 10 mL
Rifampicin	Syrup 100 mg per 5 mL, 60 mL
Risdiplam	Powder for oral solution 750 micrograms per mL, 80 mL
Risperidone	Oral solution 1 mg per mL, 100 mL
Salbutamol	Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 20
Salbutamol	Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 30
Salbutamol	Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 20

Pharmaceutical benefits to be supplied as complete packs only	
Column 1 **Listed drug**	**Column 2** **Form**
Salbutamol	Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30
Salbutamol	Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation)
Salmeterol	Powder for oral inhalation in breath actuated device 50 micrograms (as xinafoate) per dose, 60 doses
Semaglutide	Solution for injection 2 mg in 1.5 mL pre-filled pen
Semaglutide	Solution for injection 4 mg in 3 mL pre-filled pen
Silver sulfadiazine	Cream 10 mg per g, 50 g
Sirolimus	Oral solution 1 mg per mL, 60 mL
Testosterone	Transdermal cream 50 mg per mL, 50 mL
Testosterone	Transdermal gel 50 mg in 5 g sachet, 30
Testosterone	Transdermal gel (pump pack) 12.5 mg per 1.25 g dose, 60 doses, 2
Testosterone	Transdermal gel (pump pack) 23 mg per 1.15 g dose, 56 doses
Theophylline	Oral solution 133.3 mg per 25 mL, 500 mL
Timolol	Eye drops 5 mg (as maleate) per mL, 5 mL
Timolol	Eye drops 5 mg (as maleate) per mL, 5 mL (S19A)
Timolol	Eye drops (gellan gum solution) 5 mg (as maleate) per mL, 2.5 mL
Timolol	Eye drops (gellan gum solution) 5 mg (as maleate) per mL, 2.5 mL - (Timoptol-LA) (S19A)
Tiotropium	Solution for oral inhalation 2.5 micrograms (as bromide monohydrate) per actuation (60 actuations)
Tiotropium	Solution for oral inhalation 2.5 micrograms (as bromide monohydrate) per actuation (60 actuations), pack of 2
Tiotropium with olodaterol	Solution for oral inhalation containing tiotropium 2.5 micrograms (as bromide monohydrate) with olodaterol 2.5 micrograms (as hydrochloride) per dose, 60 doses
Tiotropium with olodaterol	Solution for oral inhalation containing tiotropium 2.5 micrograms (as bromide monohydrate) with olodaterol 2.5 micrograms (as hydrochloride) per dose, 60 doses, pack of 2

Pharmaceutical benefits to be supplied as complete packs only	
Column 1 **Listed drug**	**Column 2** **Form**
Tofacitinib	Oral solution 1 mg per mL, 240 mL
Tramadol	Oral drops containing tramadol hydrochloride 100 mg per mL, 10 mL
Travoprost	Eye drops 40 micrograms per mL, 2.5 mL
Travoprost with timolol	Eye drops 40 micrograms travoprost with timolol 5 mg (as maleate) per mL, 2.5 mL
Triamcinolone with neomycin, gramicidin and nystatin	Ear drops containing triamcinolone acetonide 0.9 mg with neomycin 2.25 mg (as sulfate), gramicidin 225 micrograms and nystatin 90,000 units per mL, 7.5 mL
Triamcinolone with neomycin, gramicidin and nystatin	Ear ointment containing triamcinolone acetonide 1 mg with neomycin 2.5 mg (as sulfate), gramicidin 250 micrograms and nystatin 100,000 units per g, 5 g
Trimethoprim with sulfamethoxazole	Paediatric oral suspension 40 mg-200 mg per 5 mL, 100 mL
Umeclidinium	Powder for oral inhalation in breath actuated device 62.5 micrograms (as bromide) per dose, 30 doses
Umeclidinium with vilanterol	Powder for oral inhalation in breath actuated device containing umeclidinium 62.5 micrograms (as bromide) with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses
Varenicline	Box containing 11 tablets 0.5 mg and 42 tablets 1 mg
Venetoclax	Pack containing 14 tablets venetoclax 10 mg and 7 tablets venetoclax 50 mg and 7 tablets venetoclax 100 mg and 14 tablets venetoclax 100 mg

Schedule 5—Standard formula preparations

Note: See subsection 7(3).

1 Standard formula preparations

Each extemporaneously-prepared pharmaceutical benefit described in an item of the following table is a standard formula preparation for the purposes of working out the Commonwealth price for supply of the pharmaceutical benefit, unless the benefit:

(a) varies from what is described in the item because of:
  (i) addition of an ingredient; or
  (ii) omission of an ingredient; or
  (iii) variation of the dose; or
(b) is a combination of benefits described in 2 or more items of the table.

Standard formula preparations

Column 1 Form of pharmaceutical benefit	Column 2 Standard formula preparation	Column 3 Pharmaceutical reference standard
Creams	Salicylic Acid and Sulfur Aqueous	APF
Ear Drops	Aluminium Acetate	APF
Ear Drops	Aluminium Acetate	BP
Ear Drops	Sodium Bicarbonate	APF or BP
Ear Drops	Spirit	APF
Inhalations	Benzoin and Menthol	APF
Inhalations	Menthol	APF
Inhalations	Menthol and Eucalyptus	BP 1980
Linctuses containing Codeine Phosphate	Codeine	APF
Lotions	Aluminium Acetate Aqueous	APF
Mixtures, Other	Kaolin	BPC 1968
Mixtures, Other	Magnesium Trisilicate	BPC 1968
Mixtures, Other	Magnesium Trisilicate and Belladonna	BPC 1968
Ointments, Waxes	Benzoic Acid Compound	APF or BP
Ointments, Waxes	Boric Acid, Olive Oil and Zinc Oxide	QHF
Ointments, Waxes	Salicylic Acid	APF
Ointments, Waxes	Salicylic Acid (extemporaneous formula)	BP
Paints	Podophyllin Compound	APF 16 or BP
Paints	Salicylic Acid	APF
Pastes, Other	Zinc	APF or BP

Clause 1

Standard formula preparations		
Column 1 **Form of pharmaceutical benefit**	**Column 2** **Standard formula preparation**	**Column 3** **Pharmaceutical reference standard**
Powders for Internal Use	Magnesium Trisilicate	BP

Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history

Abbreviation key—Endnote 2
The abbreviation key sets out abbreviations that may be used in the endnotes.

Legislation history and amendment history—Endnotes 3 and 4
Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

Editorial changes
The *Legislation Act 2003* authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.

If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.

Misdescribed amendments
A misdescribed amendment is an amendment that does not accurately describe how an amendment is to be made. If, despite the misdescription, the amendment can be given effect as intended, then the misdescribed amendment can be incorporated through an editorial change made under section 15V of the *Legislation Act 2003*.

If a misdescribed amendment cannot be given effect as intended, the amendment is not incorporated and "(md not incorp)" is added to the amendment history.

Endnote 2—Abbreviation key

ad = added or inserted

am = amended

amdt = amendment

C[x] = Compilation No. x

ch = Chapter(s)

cl = clause(s)

cont. = continued

def = definition(s)

Dict = Dictionary

disallowed = disallowed by Parliament

div = Division(s)

ed = editorial change

exp = expires/expired or ceases/ceased to have effect

gaz = gazette

LA = *Legislation Act 2003*

LIA = *Legislative Instruments Act 2003*

(md) = misdescribed amendment can be given effect

(md not incorp) = misdescribed amendment cannot be given effect

mod = modified/modification

No. = Number(s)

Ord = Ordinance

orig = original

p = page(s)

para = paragraph(s)/subparagraph(s) /sub-subparagraph(s)

pres = present

prev = previous

(prev…) = previously

pt = Part(s)

r = regulation(s)/Court rule(s)

reloc = relocated

renum = renumbered

rep = repealed

rs = repealed and substituted

s = section(s)/subsection(s) /rule(s)/subrule(s)/order(s)/suborder(s)

sch = Schedule(s)

SLI = Select Legislative Instrument

SR = Statutory Rules

sub ch = Sub-Chapter(s)

sub div = Subdivision(s)

sub pt = Subpart(s)

underlining = whole or part not commenced or to be commenced

Endnote 3—Legislation history

Name	Registration	Commencement	Application, saving and transitional provisions
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 114 of 2019)	29 Jan 2020 (F2020L00059)	1 Feb 2020 (s 2(1) item 1)	
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2020 (No. 1) (PB 22 of 2020)	31 Mar 2020 (F2020L00358)	1 Apr 2020 (s 2)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2020 (No. 2) (PB 35 of 2020)	30 Apr 2020 (F2020L00536)	1 May 2020 (s 2)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2020 (No. 3) (PB 43 of 2020)	29 May 2020 (F2020L00644)	1 June 2020 (s 2)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2020 (No. 4) (PB 57 of 2020)	30 June 2020 (F2020L00853)	1 July 2020 (s 2)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2020 (No. 5) (PB 69 of 2020)	31 July 2020 (F2020L00969)	1 Aug 2020 (s 2)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2020 (No. 6) (PB 80 of 2020)	27 Aug 2020 (F2020L01071)	1 Sept 2020 (s 2)	—

Endnote 3—Legislation history

Name	Registration	Commencement	Application, saving and transitional provisions
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2020 (No. 7) (PB 104 of 2020)	30 Oct 2020 (F2020L01371)	1 Nov 2020 (s 2)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2020 (No. 8) (PB 113 of 2020)	27 Nov 2020 (F2020L01486)	1 Dec 2020 (s 2)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2020 (No. 9) (PB 126 of 2020)	23 Dec 2020 (F2020L01689)	1 Jan 2021 (s 2)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2021 (No. 1) (PB 15 of 2021)	25 Feb 2021 (F2021L00154)	1 Mar 2021 (s 2)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2021 (No. 2) (PB 24 of 2021)	31 Mar 2021 (F2021L00399)	1 Apr 2021 (s 2)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2021 (No. 3) (PB 40 of 2021)	30 Apr 2021 (F2021L00519)	1 May 2021 (s 2)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2021 (No. 4) (PB 48 of 2021)	28 May 2021 (F2021L00662)	1 June 2021 (s 2)	—

Name	Registration	Commencement	Application, saving and transitional provisions
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2021 (No. 5) (PB 62 of 2021)	30 June 2021 (F2021L00905)	1 July 2021 (s 2)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2021 (No. 6) (PB 76 of 2021)	31 July 2021 (F2021L01059)	1 Aug 2021 (s 2)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2021 (No. 7) (PB 89 of 2021)	31 Aug 2021 (F2021L01216)	1 Sept 2021 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2021 (No. 8) (PB 99 of 2021)	30 Sept 2021 (F2021L01350)	1 Oct 2021 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2021 (No. 9) (PB 111 of 2021)	31 Oct 2021 (F2021L01493)	1 Nov 2021 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2022 (No. 1) (PB 25 of 2022)	31 Mar 2022 (F2022L00450)	1 Apr 2022 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2022 (No. 2) (PB 35 of 2022)	29 Apr 2022 (F2022L00645)	1 May 2022 (s 2(1) item 1)	—

Endnote 3—Legislation history

Name	Registration	Commencement	Application, saving and transitional provisions
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2022 (No. 3) (PB 45 of 2022)	27 May 2022 (F2022L00726)	1 June 2022 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2022 (No. 4) (PB 56 of 2022)	29 June 2022 (F2022L00873)	1 July 2022 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2022 (No. 5) (PB 69 of 2022)	29 July 2022 (F2022L01021)	1 Aug 2022 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2022 (No. 6) (PB 87 of 2022)	30 Sept 2022 (F2022L01305)	1 Oct 2022 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2022 (No. 7) (PB 101 of 2022)	31 Oct 2022 (F2022L01411)	1 Nov 2022 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2022 (No. 8) (PB 113 of 2022)	30 Nov 2022 (F2022L01547)	1 Dec 2022 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2022 (No. 9) (PB 122 of 2022)	23 Dec 2022 (F2022L01756)	1 Jan 2023 (s 2(1) item 1)	—

Endnote 3—Legislation history

Name	Registration	Commencement	Application, saving and transitional provisions
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No.1) (PB 3 of 2023)	31 Jan 2023 (F2023L00073)	1 Feb 2023 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No.2) (PB 12 of 2023)	28 Feb 2023 (F2023L00161)	1 Mar 2023 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No.3) (PB 23 of 2023)	31 Mar 2023 (F2023L00388)	1 Apr 2023 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No.4) (PB 36 of 2023)	28 Apr 2023 (F2023L00503)	1 May 2023 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No.5) (PB 45 of 2023)	31 May 2023 (F2023L00654)	1 June 2023 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No.6) (PB 56 of 2023)	30 June 2023 (F2023L00925)	1 July 2023 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No. 7) (PB 69 of 2023)	31 July 2023 (F2023L01052)	1 Aug 2023 (s 2(1) item 1)	—

Endnote 3—Legislation history

Name	Registration	Commencement	Application, saving and transitional provisions
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No. 8) (PB 81 of 2023)	31 Aug 2023 (F2023L01151)	1 Sept 2023 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No. 9) (PB 93 of 2023)	29 Sept 2023 (F2023L01335)	1 Oct 2023 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No. 10) (PB 106 of 2023)	31 Oct 2023 (F2023L01453)	1 Nov 2023 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No. 11) (PB 114 of 2023)	30 Nov 2023 (F2023L01582)	1 Dec 2023 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No. 12) (PB 130 of 2023)	22 Dec 2023 (F2023L01749)	1 Jan 2024 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2024 (No. 1) (PB 3 of 2024)	31 Jan 2024 (F2024L00123)	1 Feb 2024 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2024 (No. 2) (PB 17 of 2024)	29 Feb 2024 (F2024L00240)	1 Mar 2024 (s 2(1) item 1)	—

Endnote 3—Legislation history

Name	Registration	Commencement	Application, saving and transitional provisions
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2024 (No. 3) (PB 28 of 2024)	28 Mar 2024 (F2024L00409)	1 Apr 2024 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2024 (No. 4) (PB 41 of 2024)	30 Apr 2024 (F2024L00500)	1 May 2024 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2024 (No. 5) (PB 54 of 2024)	31 May 2024 (F2024L00605)	1 June 2024 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2024 (No. 6) (PB 70 of 2024)	28 June 2024 (F2024L00820)	1 July 2024 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2024 (No. 7) (PB 78 of 2024)	31 July 2024 (F2024L00948)	1 Aug 2024 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2024 (No. 8) (PB 87 of 2024)	30 Aug 2024 (F2024L01097)	1 Sept 2024 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2024 (No. 9) (PB 97 of 2024)	30 Sept 2024 (F2024L01240)	1 Oct 2024 (s 2(1) item 1)	—

Endnote 3—Legislation history

Name	Registration	Commencement	Application, saving and transitional provisions
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2024 (No. 10) (PB 113 of 2024)	31 Oct 2024 (F2024L01391)	1 Nov 2024 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2024 (No. 11) (PB 126 of 2024)	29 Nov 2024 (F2024L01533)	1 Dec 2024 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2024 (No. 12) (PB 140 of 2024)	24 Dec 2024 (F2024L01734)	1 Jan 2025 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2025 (No. 1) (PB 3 of 2025)	31 Jan 2025 (F2025L00064)	1 Feb 2025 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2025 (No. 2) (PB 15 of 2025)	28 Feb 2025 (F2025L00217)	1 Mar 2025 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2025 (No. 3) (PB 26 of 2025)	31 Mar 2025 (F2025L00456)	1 Apr 2025 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2025 (No. 4) (PB 42 of 2025)	30 Apr 2025 (F2025L00536)	1 May 2025 (s 2(1) item 1)	—

Endnote 3—Legislation history

Name	Registration	Commencement	Application, saving and transitional provisions
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2025 (No. 5) (PB 57 of 2025)	30 May 2024 (F2025L00624)	1 June 2025 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2025 (No. 6) (PB 76 of 2025)	30 June 2025 (F2025L00777)	1 July 2025 (s 2(1) item 1)	—
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2025 (No. 7) (PB 86 of 2025)	31 July 2025 (F2025L00879)	1 Aug 2025 (s 2(1) item 1)	—

Endnote 4—Amendment history

Provision affected	How affected
Part 1	
s 2	rep LA s 48D
s 4	rep LA s 48C
s 6	am F2020L00853
	ed C4
Part 2	
s 7	am F2020L00853
	ed C4
Schedule 1	
Schedule 1	am F2023L00161; F2023L00654; F2023L01335; F2023L01453; F2023L01582; F2024L00500; F2024L00820; F2024L00948; F2024L01240; F2024L01734; F2025L00217
Schedule 3	
Schedule 3	am F2020L01071; F2021L00905; F2022L00726; F2022L01021; F2023L00073; F2023L00503; F2023L00925; F2023L01052; F2023L01582; F2023L01749; F2024L00240; F2024L00409; F2024L00820; F2024L01391; F2025L00536; F2025L00624; F2025L00777; F2025L00879
Schedule 4	
Schedule 4	am F2020L00358; F2020L00536; F2020L00644; F2020L00853; F2020L00969; F2020L01371; F2020L01486; F2020L01689; F2021L00154; F2021L00399; F2021L00519; F2021L00662; F2021L01059; F2021L01216; F2021L01350; F2021L01493; F2022L00450; F2022L00645; F2022L00873; F2022L01021; F2022L01305; F2022L01411; F2022L01547; F2022L01756; F2023L00073; F2023L00161; F2023L00388; F2023L00503; F2023L00654; F2023L00925; F2023L01052; F2023L01151; F2023L01335; F2023L01453; F2023L01582; F2023L01749; F2024L00123; F2024L00240; F2024L00409; F2024L00500; F2024L00605; F2024L00820; F2024L00948; F2024L01097; F2024L01240; F2024L01391; F2024L01533; F2025L00064; F2025L00217; F2025L00456; F2025L00536; F2025L00624; F2025L00777; F2025L00879
Schedule 5	
Schedule 5	am F2021L01059
Schedule 6	rep LA s 48C